Background Several measures recommended by the WHO Framework Convention on Tobacco Control have not been implemented in the European Union, despite changes in the legislation such as the Tobacco Products Directive (TPD). This study aims to understand smokers’ and recent quitters’ levels of support for tobacco control measures that go beyond the TPD during and after its implementation.
Methods Data from wave 1 (2016, n=6011) and wave 2 (2018, n=6027) of the EUREST-PLUS International Tobacco Control Policy Evaluation Project Six European Countries Survey, a cohort of adult smokers in Germany, Greece, Hungary, Poland, Romania, Spain were used to estimate the level of support for seven different tobacco control measures, overall and by country.
Results In 2018, the highest support was for implementing measures to further regulate tobacco products (50.5%) and for holding tobacco companies accountable for the harm caused by smoking (48.8%). Additionally, in 2018, 40% of smokers and recent quitters supported a total ban on cigarettes and other tobacco products within ten years, if assistance to quit smoking is provided. Overall, support for tobacco control measures among smokers and recent quitters after the implementation of the TPD remained stable over time.
Conclusion There is considerable support among smokers and recent quitters for tobacco control measures that go beyond the current measures implemented. A significant percentage of smokers would support a ban on tobacco products in the future if the government provided assistance to quit smoking. This highlights the importance of implementing measures to increase smoking cessation in conjunction with other policies.
- public opinion
- public policy
- end game
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Twitter @ZatonskiMateusz, @gfong570, @stvfdz
Collaborators EUREST-PLUS Consortium: Andrea Glahn, Dominick Nguyen, Katerina Nikitara, Cornel Radu-Loghin, Polina Starchenko (European Network on Smoking and Tobacco Prevention (ENSP), Belgium). Aristidis Tsatsakis, Charis Girvalaki, Chryssi Igoumenaki, Sophia Papadakis, Aikaterini Papathanasaki, Manolis Tzatzarakis, Alexander I Vardavas (University of Crete (UOC), Greece). Nicolas Bécuwe, Lavinia Deaconu, Sophie Goudet, Christopher Hanley, Oscar Rivière (Kantar Public, Belgium). Judit Kiss, Anna Piroska Kovacs (Smoking or Health Hungarian Foundation (SHHF), Hungary). Ann McNeill, Katherine East (Kings College London (KCL), United Kingdom). Sarah Kahnert (Cancer Prevention Unit and WHO Collaborating Centre for Tobacco Control, German Cancer Research Center (DKFZ), Germany). Yannis Tountas, Panagiotis Behrakis, Filippos T Filippidis, Christina Gratziou, Theodosia Peleki, Ioanna Petroulia, Chara Tzavara (National and Kapodistrian University of Athens (UoA, Greece). Marius Eremia, Lucia Lotrean, Florin Mihaltan (Aer Pur Romania, Romania). Esteve Fernández, Olena Tigova, Yolanda Castellano, Marcela Fu, Sarah O. Nogueira (Catalan Institute of Oncology, ICO; Bellvitge Biomedical Research Institute, IDIBELL, Catalonia, Spain).
Gernot Rohde, Tamaki Asano, Claudia Cichon, Amy Far, Céline Genton, Melanie Jessner, Linnea Hedman, Christer Janson, Ann Lindberg, Beth Maguire, Sofia Ravara, Valérie Vaccaro, Brian Ward (European Respiratory Society, ERS, Switzerland). Marc Willemsen, Hein de Vries, Karin Hummel, Gera E Nagelhout (Maastricht University, the Netherlands). Witold A Zatoński, Aleksandra Herbeć, Kinga Janik-Koncewicz, Krzysztof Przewoźniak (Health Promotion Foundation, HPF, Poland). Thomas K Agar, Shannon Gravely, Mary E Thompson (University of Waterloo, UW, Canada).
Contributors Conceptualised and designed the study: SON, PD, UM, TD, ACT, KP, PK, GF, CIV and EF. Contributed to the strategy of analysis: SON, PD, UM, MF, OT, YC and EF. Analysed data: PD. Interpreted data results: SON, PD, MF, UM, SCH, CK, MZZ and EF. Drafted manuscript: SON. Critically revised manuscript: All authors. Approved final manuscript version: All authors.
Funding The EUREST-PLUS project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 681 109 (CIV) and the University of Waterloo (GF). Additional support was provided to the University of Waterloo by the Canadian Institutes of Health Research (FDN-148477). GF was supported by a Senior Investigator Grant from the Ontario Institute for Cancer Research. The Tobacco Control research Group (IDIBELL) is partly supported by Ministry of Universities and Research, Government of Catalonia (2017SGR319). EF is partly supported by the Instituto Carlos III and cofunded by the European Regional Development Fund (FEDER) (INT16/00211 and INT17/00103), Government of Spain. SON has received funding from the European Union’s 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No. 713 673. SON has received financial support through the 'La Caixa' INPHINIT Fellowship Grant for Doctoral studies at Spanish Research Centres of Excellence, 'La Caixa' Banking Foundation, Barcelona, Spain (LCF/BQ/DI17/11620022).
Disclaimer The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Competing interests GF has served as an expert witness on behalf of governments in litigation involving the tobacco industry. KP reports grants and personal fees from the Polish League Against Cancer, outside the submitted work.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.